Rimonabant
As of the edition of 20 October 2026, Rimonabant is a small molecule: withdrawn from the market in 2009; acts on CNR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2009
- Kind
- Small molecule
- Withdrawn from market
- 16 January 2009 (in some regions)
- Registered trials
- 44, 19 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Heart and blood vessels; Mental health; Nervous system; Chemically induced
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CNR1 | Cannabinoid receptor 1 | P21554 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 4 | 3 | 0 | 1 |
| Phase 3 | 35 | 18 | 0 | 17 |
| Phase 4 | 2 | 0 | 0 | 1 |
| All trials | 44 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sanofi | Lead sponsor of trials | 2001 to now |